We are pleased to announce an exciting strategic partnership between REGENXBIO and Nippon Shinyaku for the development and commercialization of RGX-121 and RGX-111 for the treatment of MPS II and MPS I. #JPM2025 Learn more: https://lnkd.in/e4ZYUzWy
REGENXBIO
Biotechnology Research
Rockville, Maryland 34,349 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
Get directions
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO
Updates
-
We are looking forward to connecting with industry leaders, sharing insights, and exploring opportunities to advance innovation in healthcare at the Longwood Healthcare Leaders Conference! REGENXBIO’s EVP of Commercial Strategy & Operations, Ram Palanki, will be joining a panel to discuss innovation in commercial models. https://lnkd.in/esNkzCWY #longwoodhealthcareleaders, #SanFranciscoCEO
-
The National MPS Society Annual Family Conference is always a highlight for our team. It was great joining the MPS community in Orlando for meaningful discussion about progress being made in MPS research. Thank you to the National MPS Society for 50 years of unwavering support for families in the MPS community!
-
-
We’re excited to attend the National MPS Society’s Annual Family Conference this week in Orlando, FL, to honor and celebrate the organization’s 50 years of support, strength, and success for MPS families. REGENXBIO’s CEO, Curran Simpson, will join industry leaders for the CEO Fireside Chat and Dawn Phillips will share an update on our RGX-121 clinical program for the treatment of MPS II. We look forward to seeing the MPS community there!
🌟✨ Celebrate, Connect, and Discover: Join Us at the 38th Annual Family & Scientific Conference! ✨🌟 December 19-21, 2024, the National MPS Society is bringing the MPS and ML community together in Orlando, Florida, to celebrate 50 years of hope and progress! Our 38th Annual Family & Scientific Conference will feature cutting-edge research, meaningful connections, and opportunities to honor the incredible milestones we’ve achieved together. This year, we’re adding a touch of magic! While you engage in impactful sessions and connect with others, you'll also have the chance to make memories at nearby Walt Disney World. 💼 Whether you’re a researcher, family member, advocate, or supporter, this is your chance to make an impact and be inspired. 🌐 Register now: https://ow.ly/8Svn50UcZR5 ✨ Check out our free Disney tips: https://ow.ly/e0C850UcZOp Whether you’re coming for the science, the connections, or the celebrations, this is one conference you won’t want to miss. Let’s make magic together in Orlando! 🏰💜 #NMPSSC24 #NationalMPSSociety #50Years #DisneyWorld #MPS #ML #RareDisease #HurlerSyndrome #HunterSyndrome #Sanfilippo #MorquioSyndrome #MaroteauxLamySyndrome #SlySyndrome #HyaluronidaseSyndrome
-
-
ICYMI, REGENXBIO’s VP of Regulatory and Corporate Strategy, Nina Hunter, recently joined Cell & Gene Live to discuss the regulatory challenges and strategies involved in bringing innovative AAV therapies to patients. Listen to the recording here: https://lnkd.in/e5WKrNWd
-
-
This week, we were pleased to welcome Matthew Ellinwood, Amy Gaviglio, Terri L. Klein, and Wendy B. Spaulding, all leaders at the forefront of expanding access to newborn screening and its importance for rare diseases, specifically MPS, in the United States. Thank you for your insights and for your advocacy.
-
-
At our recent all company meeting, we announced our President’s Award winner, Mona Sharma! Mona has been instrumental in our RGX-121 program for the treatment of MPS II. Join us in congratulating Mona for this well-deserved recognition!
-
-
REGENXBIO’s VP of Regulatory and Corporate Strategy, Nina Hunter, joins Cell & Gene Live to discuss the regulatory challenges and strategies involved in bringing innovative AAV therapies to patients. Register Here: https://lnkd.in/eKkzSM4t
-
Similar pages
Browse jobs
Stock
RGNX
NASDAQ
20 minutes delay
$6.95
-0.56 (-7.457%)
- Open
- 7.4
- Low
- 6.56
- High
- 7.7
Data from Refinitiv
See more info on